脓毒症和危重病中的促解决脂质介质。
Pro-resolving lipid mediators in sepsis and critical illness.
机构信息
William Harvey Research Institute, Barts and the London School of Medicine.
Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, London, UK.
出版信息
Curr Opin Clin Nutr Metab Care. 2020 Mar;23(2):76-81. doi: 10.1097/MCO.0000000000000633.
PURPOSE OF REVIEW
Sepsis is a life-threatening condition caused by a dysregulated host response to infection that remains a huge clinical challenge. Recent evidence indicates that bioactive lipid mediators derived from polyunsaturated fatty acids termed specialized pro-resolving mediators (SPMs) are promising new candidates for treating critical illness.
RECENT FINDINGS
We highlight herein the protective actions of SPMs in experimental sepsis, cardiac dysfunction, and also lung and cerebral injury, and discuss their mechanisms of action. We also emphasize that failed resolution responses and dysregulated SPM pathways may provide an explanation for the ongoing chronic inflammation in many diseases including chronic heart failure.
SUMMARY
Importantly, monitoring plasma SPM profiles can predict patient outcomes in sepsis indicating their utility as new early biomarkers that may help stratify patients upon ICU admission.
目的综述
败血症是一种由宿主对感染的失调反应引起的危及生命的疾病，仍然是一个巨大的临床挑战。最近的证据表明，源自多不饱和脂肪酸的生物活性脂质介质，称为特异性促解决介质（SPM），是治疗危重病的有前途的新候选药物。
最近的发现
我们在此强调了 SPM 在实验性败血症、心功能障碍以及肺和脑损伤中的保护作用，并讨论了它们的作用机制。我们还强调，解决反应失败和 SPM 途径失调可能为许多疾病（包括慢性心力衰竭）中的持续慢性炎症提供解释。
总结
重要的是，监测血浆 SPM 谱可以预测败血症患者的预后，表明它们可用作新的早期生物标志物，可能有助于在 ICU 入院时对患者进行分层。
Zotero 插件